Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

01.03.2016 | Original Article

Obstetric Complications and Management in Chronic Myeloid Leukemia

verfasst von: Minakshi Rohilla, Rakhi Rai, Uday Yanamandra, Neelam Chaudhary, Pankaj Malhotra, Neelam Varma, Vanita Jain, G. R. V. Prasad, Jasvinder Kalra, Subhash C. Varma

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic myeloid leukaemia (CML) is amongst the most common haematological malignancies encountered in adults. The younger age of onset and increased incidence of CML in Indians leads to higher chances of encountering it in pregnancy. Pregnancy in CML is a complex situation as first line therapy with tyrosine kinase inhibitors (TKI), is fraught with multiple fetal safety issues. The fetal aspects have been elucidated in literature, but there is scarcity of information on the obstetric outcome per se in presence of CML, excluding the influence of TKI. Obstetric outcomes of 5 pregnancies in four patients with CML are being reported. Literature on interplay of CML and bleeding or thrombotic manifestations is reviewed. The major complications encountered were antepartum (APH) and postpartum haemorrhage (PPH), preterm labour, intrauterine growth retardation and intrauterine fetal death. Patients in the reproductive age group with diagnosis of CML should be carefully counseled regarding the effect of disease and TKI on the maternal-fetal health. Bleeding complications, particularly APH and PPH may be encountered in CML patients. Close coordination of the obstetrician, haematologist, and neonatologist is required in managing these cases successfully. The need for absolute contraception till the remission of disease needs to be emphasized for further pregnancies.
Literatur
2.
Zurück zum Zitat Malhotra P, Varma N, Varma S (2013) A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh. Indian J Med Paediatr Oncol 34(3):186–188PubMedCentralCrossRefPubMed Malhotra P, Varma N, Varma S (2013) A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh. Indian J Med Paediatr Oncol 34(3):186–188PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Al Sabty F, Demeckova E, Mistrik M (2008) Leukemia in Pregnancy. Bratisl Lek Listy 109(8):364–366 Al Sabty F, Demeckova E, Mistrik M (2008) Leukemia in Pregnancy. Bratisl Lek Listy 109(8):364–366
4.
Zurück zum Zitat Ali R, Ozkalemkas F, Ozkocaman V, Ozcelice T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of literature. Jpn J Clin Oncol 34(4):215–2172CrossRefPubMed Ali R, Ozkalemkas F, Ozkocaman V, Ozcelice T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of literature. Jpn J Clin Oncol 34(4):215–2172CrossRefPubMed
5.
7.
Zurück zum Zitat Yadav U, Solanki SL, Yadav R (2013) Chronic myeloid leukaemia with pregnancy: successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery. J Can Res Ther 9:484–486CrossRef Yadav U, Solanki SL, Yadav R (2013) Chronic myeloid leukaemia with pregnancy: successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery. J Can Res Ther 9:484–486CrossRef
8.
Zurück zum Zitat Martin J, Ramesh A, Devadasan L, Palaniappan, Martin JJ (2011) An uneventful pregnancy and delivery, in a case with chronic myeloid leukaemia on imatinib. Indian J Med Paediatr Oncol 32:109–111PubMedCentralCrossRefPubMed Martin J, Ramesh A, Devadasan L, Palaniappan, Martin JJ (2011) An uneventful pregnancy and delivery, in a case with chronic myeloid leukaemia on imatinib. Indian J Med Paediatr Oncol 32:109–111PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Sagili H, Reddi RP (2014) Unusual presentation of CML in pregnancy. J Case Rep Stud 1:602 Sagili H, Reddi RP (2014) Unusual presentation of CML in pregnancy. J Case Rep Stud 1:602
10.
Zurück zum Zitat Wang DP, Liang MY, Zhang XH, Wang SM (2010) Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukaemia. Zhonghua Fu Chan Ke Za Zhi 45(10):735–739 (Chinese)PubMed Wang DP, Liang MY, Zhang XH, Wang SM (2010) Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukaemia. Zhonghua Fu Chan Ke Za Zhi 45(10):735–739 (Chinese)PubMed
11.
Zurück zum Zitat Muta T, Sawada Y, Moriyama Y, Seike Y, Tokuyama T, Ueda Y, Fujisaki T (2010) Chronic myeloid leukaemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care. Rinsho Ketsueki 51(12):1769–1774 (Japanese)PubMed Muta T, Sawada Y, Moriyama Y, Seike Y, Tokuyama T, Ueda Y, Fujisaki T (2010) Chronic myeloid leukaemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care. Rinsho Ketsueki 51(12):1769–1774 (Japanese)PubMed
12.
Zurück zum Zitat Vignal CV, Lourenço DM, Noguti MA, Chauffaille Mde L, Kerbauy J (1997) Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases. Sao Paulo Med J. Nov-Dec 115(6):1575–1579CrossRef Vignal CV, Lourenço DM, Noguti MA, Chauffaille Mde L, Kerbauy J (1997) Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases. Sao Paulo Med J. Nov-Dec 115(6):1575–1579CrossRef
13.
Zurück zum Zitat Cervantes F, Sanz C, Bosch F, Rozman C (1991) Causes of death in chronic myeloid leukaemia. Analysis of 109 patients. Sangre (Barc) 36(3):183–186 Cervantes F, Sanz C, Bosch F, Rozman C (1991) Causes of death in chronic myeloid leukaemia. Analysis of 109 patients. Sangre (Barc) 36(3):183–186
14.
Zurück zum Zitat Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63(2):101–106CrossRefPubMed Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63(2):101–106CrossRefPubMed
15.
Zurück zum Zitat Wehmeier A, Fricke S, Scharf RE, Schneider W (1990) A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol 45(4):191–197CrossRefPubMed Wehmeier A, Fricke S, Scharf RE, Schneider W (1990) A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol 45(4):191–197CrossRefPubMed
16.
Zurück zum Zitat Bazarbashi MS, Smith MR, Karanes C, Zielinski I, Bishop CR (1991) Successful management of Ph chromosome chronic myelogenous leukaemia with leukapheresis during pregnancy. Am J Hematol 38:235–257CrossRefPubMed Bazarbashi MS, Smith MR, Karanes C, Zielinski I, Bishop CR (1991) Successful management of Ph chromosome chronic myelogenous leukaemia with leukapheresis during pregnancy. Am J Hematol 38:235–257CrossRefPubMed
17.
Zurück zum Zitat Reichel RP, Linkesch W, Schetitska D (1992) Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia. Br J Haematol 82:472–478CrossRefPubMed Reichel RP, Linkesch W, Schetitska D (1992) Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia. Br J Haematol 82:472–478CrossRefPubMed
18.
Zurück zum Zitat Sharma K, Puniyani RR, Bhat SV, Advani SH, Hegde U, Rao S (1992) Blood viscosity parameter correlation with types of leukaemia. Physiol Chem Phys Med NMR 24(2):159–164PubMed Sharma K, Puniyani RR, Bhat SV, Advani SH, Hegde U, Rao S (1992) Blood viscosity parameter correlation with types of leukaemia. Physiol Chem Phys Med NMR 24(2):159–164PubMed
19.
Zurück zum Zitat Hansen WF, Fretz P, Hunter SK, Yankowitz J (2001) Leukemia in pregnancy and foetal response to m ultiagent chemotherapy. Obstet Gynecol 97(5 Pt 2):809–812CrossRefPubMed Hansen WF, Fretz P, Hunter SK, Yankowitz J (2001) Leukemia in pregnancy and foetal response to m ultiagent chemotherapy. Obstet Gynecol 97(5 Pt 2):809–812CrossRefPubMed
20.
Zurück zum Zitat Apperly J (2009) Issues of Imatinib and pregnancy outcome. J Natl Compr Cancer Netw 7(10):1–9 Apperly J (2009) Issues of Imatinib and pregnancy outcome. J Natl Compr Cancer Netw 7(10):1–9
21.
Zurück zum Zitat Apperly J. (2009) CML in pregnancy and childhood. Best practice & Research Clinical Hematology.; 455-475 Apperly J. (2009) CML in pregnancy and childhood. Best practice & Research Clinical Hematology.; 455-475
Metadaten
Titel
Obstetric Complications and Management in Chronic Myeloid Leukemia
verfasst von
Minakshi Rohilla
Rakhi Rai
Uday Yanamandra
Neelam Chaudhary
Pankaj Malhotra
Neelam Varma
Vanita Jain
G. R. V. Prasad
Jasvinder Kalra
Subhash C. Varma
Publikationsdatum
01.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0519-0

Weitere Artikel der Ausgabe 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.